ClinicalTrials.gg
RecruitingNCT07136753MIBREASTUpdated Aug 22, 2025

MIBREAST Making in Immediate Breast REconstruction And the Measurement of the EffectS of RadioTherapy

An observational study in Breast Cancer, sponsored by Royal Marsden NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by Royal Marsden NHS Foundation Trust · Observational

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Breast Neoplasms by Royal Marsden NHS Foundation Trust — 5 open to participants now, 9 under way, none of them phase 3. Breast Neoplasms · Royal Marsden NHS Foundation Trust.

Planned enrollment
4th of 12
300 · median 150
Started
2024
with 2 others
Observational
12 of 42
3 open now
Registered
41st of 42
by date

Among the 42 studies in Breast Neoplasms by Royal Marsden NHS Foundation Trust, this one is the 4th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2024, is one of 12 observational ones, and was the 41st registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 42 studies in Breast Neoplasms by Royal Marsden NHS Foundation Trust are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Breast Neoplasms by Royal Marsden NHS Foundation Trust, or all of them as a file.
02

Study summary

Patients who require a removal of a breast (mastectomy) for breast cancer or future risk reduction often have immediate breast reconstruction (IBR). This can be performed using either an implant or the patient's own body fat to recreate the breast shape.

Patients can find it difficult to imagine their own post-surgery appearance. Using 3D surface imaging (3D-SI) can change a patient's pictures to show them how they might look after surgery, known as a simulation. Some patients may find 3D-SI and simulation gives them confidence in their expectations and others may not feel it helps much.

This study will investigate the following 3 questions:

  1. Whether 3D-SI and simulation can improve patient confidence about their likely post-surgery appearance
  2. Whether 3D-SI measurement of breast shape helps in surgical planning and reduces the need for later adjustment surgery to improve symmetry, especially in patients having a mastectomy on one side only
  3. How much radiotherapy changes breast reconstructions over time using 3D- SI to objectively measure this. For this study the follow up for some women who do and some who do not have radiotherapy after breast reconstruction.

3D surface imaging may improve surgeon understanding of breast shape, prior to surgery. In cases where there is a high risk of breast cancer recurrence patients are offered radiotherapy to the breast, either before or after surgery. Radiotherapy has a negative impact on the reconstructed breast, and may cause it to shrink and change position but the effect of radiotherapy has never been accurately quantified. This study will be investigating the following:

  1. Whether 3D-SI measurement of breast shape helps in surgical planning and reduces the need for later adjustment surgery to improve symmetry, especially in patients having a mastectomy on one side only
  2. How much radiotherapy changes breast reconstructions over time using 3D- SI to objectively measure this. For this study the follow up some women who do and some who do not have radiotherapy after breast reconstruction.
Read the detailed description

Approximately 40% of all women diagnosed with breast cancer (BC) will require a mastectomy and a large proportion (60%) of these will choose to have an immediate breast reconstruction (IBR).

Patient satisfaction with physical appearance after completion of their BC treatment has a well-documented association not only with their psychological wellbeing but also improved quality of life. Due to advances in oncological therapies, BC patients now have excellent survival rates of 85% at five years and 75% at ten years meaning that more women survive to experience the long-term impact of surgical and radiotherapy treatments and highlights the importance of improving aesthetic outcome as a survivorship focus.

3D-surface imaging (3D-SI) and simulation is frequently used to demonstrate cosmetic breast augmentation outcomes in the private sector and is increasingly being used in breast cancer surgery.

Effective communication of the post-operative aesthetic outcome and the possible requirement of adjustment surgery to patients is a central part of the informed consent process. Women sometimes struggle to decide between breast-conserving treatment and mastectomy with or without reconstruction. Those that want reconstruction to have the option of using a silicone implant, or their own tissue, transplanted from the abdomen or inner thigh (an autologous flap). Consultations focus on the patient's desires and expectations, and the surgeon's explanation of what is technically possible, the benefits and compromises, until a mutual understanding is reached. This can however be challenging, particularly when attempting to predict the effects of adjuvant radiotherapy on the reconstructed breast. Traditionally, surgeons have used diagrams or 2D clinical photographs of other patients who have had surgery to demonstrate the predicted post-operative appearance. Many patients have reported that they find these methods unhelpful and confusing, as the wide variety of body habitus, breast shape, skin tone and surgical options mean that it is unlikely that a woman will see images adequately illustrating her own unique outcome.

The hypothesise that viewing 3D simulations of their own likely appearance after mastectomy and breast reconstruction will give women more confidence and certainty as they approach surgery. There are not yet in a position to use 3D-SI as a decision-support tool.

The overarching aim of this study is to evaluate the utility of 3D-SI in simulation and measurement of outcome of immediate breast reconstruction.

Hypothesis 1 - Impact of 3D Simulation on Shared Decision Making Women who see a simulation of their IBR outcome will have more confidence in their decision-making about IBR options.

Hypothesis 2 - Impact of 3D-SI on Elective Surgical Revision rate A better understanding of breast shape may reduce the need for elective surgical revisions such as volume-adjustment procedures (lipofilling or liposuction) in the reconstructed breast.

Hypothesis 3 - Impact of Radiotherapy on IBR The hypothesise that immediate breast reconstructions that receive radiotherapy undergo greater change in shape and position over time.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Decision making
  • Reconstruction
  • Risk reducing surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients considering breast reconstruction following mastectomy for cancer or risk reduction.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female
  • Aged > 18
  • Undergoing immediate breast reconstruction (autologous or implant based) follow mastectomy for breast cancer or as a risk-reducing strategy
  • Available to attend 3D-SI appointments at specified intervals

Exclusion criteria

Exclusion Criteria:

  • Lack of capacity
  • Language barrier that prevents patients from understanding the English questionnaires
  • Visual impairment
  • Unable to answer study questionnaires
  • Disability that may prevent appropriate positioning during the imaging process
  • Unable to attend for photography
  • Requiring delayed reconstruction or no longer considering a reconstruction
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Standard of Care

    2D catalogue of photographs of other patients who have had surgery to demonstrate the predicted post-operative appearance

  • 3D Surface Imaging

    3D Simulation of patients own breast to show them how they might look after surgery

06

What researchers measure

Primary outcomes

  1. Difference in Visual Analogue Scale Score

    Difference in mean visual analogue scale (VAS) for the question 'How confident is one in knowing how their breasts are likely to look after treatment?' VAS score is on a scale from 0-10 (0 indicates not at all confident and 10 indicates very confident)

    Time frame: Preioperative/Periprocedural

Secondary outcomes

  1. Difference in decisional conflict scale score

    Difference in Decisional Conflict Scale (DCS) score for women who see and do not see their simulated reconstruction

    Time frame: Perioperative/Periprocedural

  2. Comparison between 3D and SoC anthropometric measurements

    Comparison between Crisalix and routine tape measure anthropometric measurements.The same unit of measurement will be used for the anthropometric distances (i.e.sternal notch to nippple, nipple to nipple, nipple to midline, nipple to lateral fold, nipple to inframammary fold and breast diameter) measured in cm for both 3D-SI and tape measurements

    Time frame: Perioperative/Periprocedural

  3. Thematic analysis of surgeons' experience

    Thematic analysis of surgeons' experience

    Time frame: 1 year

  4. Evaluation of actual outcome against simulated appearance by panel assessment using a Likert scale

    Evaluation of the actual outcome against the simulated appearance

    Time frame: through study completion, an average of 1 year

  5. Comparison of patient satisfaction with the breast, and with information given (BREAST-Q domains) by randomisation group

    Comparison of patient satisfaction with the breast, and with information given (BREAST-Q domains) by randomisation group (3D simulation vs standard of care) at 1 and 2 years. To further undertake a panel assessment of 3D simulated outcomes and compare these to 2D images of actual post-operative appearance at 1 year after surgery. The panel will consist of consultant breast and plastic surgeons who will indicate likeness of simulated appearance to actual appearance on a Likert scale of 1-5 (score of 1 indicates that simulation is not at a similar to actual outcome and 5 indicates very similar appearance).

    Time frame: through study completion, an average of 1 year

  6. Using 3D-SI to classify breast shape

    Using 3D-SI to classify breast shape

    Time frame: through study completion, an average of 1 year

  7. Impact of breast shape classification on elective secondary revisions (ESRs) and reconstructive outcomes

    Impact of breast shape classification on elective secondary revisions (ESRs) and reconstructive outcomes. 3D-SI measurements (distances in cm and volume in cc) will be captured and using a principal component analysis different breast shape subgroups will be derived. Following this, to then compare breast shape type, primary surgery type (e.g. implant or autologous reconstruction) and whether the patient has had elective surgical revision. This will be an exploratory process to determine whether there is a relationship between breast shape and need for revision surgery. There is currently no existing tool to measure this. anthropometric measurements (sternal notch to nipple, nipple to nipple, nipple to inframammary fold, nipple to midline, nipple to lateral fold, breast diameter) are entered in cm and breast volume is entered in cc.

    Time frame: through study completion, an average of 1 year

  8. Documented relationship between donor tissue availability and breast volume

    The intend to examine the relationship between the available abdominal donor tissue and required breast volume for patients undergoing autologous breast reconstruction. A comparison of the available abdominal tissue (measured in cc) using manual segmentation of the CT scan and the required breast volume measured in cc on the pre-operative 3D-SI measurement. We would like to investigate whether a greater degree of mismatch (abdominal volume in cc divided by breast volume in cc) is related to an increased likelihood of requiring revisional surgery.

    Time frame: through study completion, an average of 1 year

  9. Documented changes in shape of IBR with and without radiotherapy

    volume Documented changes in shape of IBR with and without radiotherapy

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2026, 24 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 24 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2025
First posted
Aug 22, 2025
StartActual
Sep 12, 2024
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2030
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07136753
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Sep 12, 2024
Primary completion
Sep 2026 (estimated)
Completion
Sep 2030 (estimated)
Last update
Aug 22, 2025

Study contacts

Jeane Guevara
Contact
MIBREAST@rmh.nhs.uk
+44 20 3186 5420

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion